Gene therapy AMT-130 slows Huntington's disease progression by 75% in a small trial, triggering a surge in uniQure's stock price.
The U.S. General Services Administration strikes an 18-month agreement with Elon Musk's xAI to make Grok AI models available to federal agencies, raising concerns about the model's suitability for government use.
Gene therapy AMT-130 slows Huntington's disease progression by 75% in a small trial, triggering a surge in uniQure's stock price.
The U.S. General Services Administration strikes an 18-month agreement with Elon Musk's xAI to make Grok AI models available to federal agencies, raising concerns about the model's suitability for government use.